Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;90(4):e70161.
doi: 10.1111/1750-3841.70161.

Resinacein S, a novel triterpenoid from functional mushroom Ganoderma resinaceum, curbs obesity by regulating thermogenesis and energy metabolism

Gang Wei  1   2 , Feng-Jie Shen  1 , Jun-Li Liu  3 , Jian-Hua Zhao  3 , Rong-Rong Xie  1 , Jing Lu  1 , Chen-Yang Zhang  1 , Yuan Wang  1 , Ting-Ting Shi  1 , Fang-Yuan Yang  1 , Shu-Qin Chen  4 , Yan-Jie Huang  5 , Jin-Kui Yang  1
Affiliations

Resinacein S, a novel triterpenoid from functional mushroom Ganoderma resinaceum, curbs obesity by regulating thermogenesis and energy metabolism

Gang Wei et al. J Food Sci. 2025 Apr.

Abstract

Ganoderma mushrooms are popularly used as dietary supplements to promote health around the world. However, their potential applications for the prevention and treatment of obesity needs to be further investigated. In this study, we isolated a novel triterpenoid from Ganoderma resinaceum, Resinacein S (Res S), and determined its absolute configuration. We reported that Res S treatment significantly inhibited the high-fat HF diet-induced body weight gain though increased thermogenesis and energy metabolism. Specifically, treatment with Res S promoted brown adipose tissue activation and browning of inguinal white adipose tissue, improving whole-body glucose and lipid homeostasis. Mechanistically, Res S treatment induced the expression of thermogenic genes and related protein, for example, uncoupling protein 1 and mitochondrial biogenesis in a cell-autonomous manner by activating the AMPK-PGC1α signaling pathway. These findings identify Res S as a potential therapeutic alternative for obesity in the setting of its increasingly high prevalence. HIGHLIGHTS: Resinacein S (Res S) exhibited potent anti-obesity effects in high-fat diet-fed mice; Res S treatment significantly promoted brown adipose tissue activation and browning of inguinal white adipose tissue; Res S treatment stimulated UCP1 expression and enhanced mitochondrial function; Res S induced adipocyte thermogenic activity through activating the AMPK-PGC1α axis.

Keywords: brown adipose tissue; ganoderma triterpenoids; glucose homeostasis; metabolic syndrome; white adipose browning.

PubMed Disclaimer

References

REFERENCES

    1. Bartelt, A., Bruns, O. T., Reimer, R., Hohenberg, H., Ittrich, H., Peldschus, K., Kaul, M. G., Tromsdorf, U. I., Weller, H., Waurisch, C., Eychmüller, A., Gordts, P. L., Rinninger, F., Bruegelmann, K., Freund, B., Nielsen, P., Merkel, M., & Heeren, J. (2011). Brown adipose tissue activity controls triglyceride clearance. Nature Medicine, 17(2), 200–205.
    1. Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., Kajimura, S., Zingaretti, M. C., Vind, B. F., Tu, H., Cinti, S., Højlund, K., Gygi, S. P., & Spiegelman, B. M. (2012). A PGC1‐α‐dependent myokine that drives brown‐fat‐like development of white fat and thermogenesis. Nature, 481(7382), 463–468.
    1. Carpentier, A. C., Blondin, D. P., Haman, F., & Richard, D. (2023). Brown adipose tissue‐a translational perspective. Endocrine Reviews, 44(2), 143–192.
    1. Chen, S., Liu, X., Peng, C., Tan, C., Sun, H., Liu, H., Zhang, Y., Wu, P., Cui, C., Liu, C., Yang, D., Li, Z., Lu, J., Guan, J., Ke, X., Wang, R., Bo, X., Xu, X., Han, J., & Liu, J. (2021). The phytochemical hyperforin triggers thermogenesis in adipose tissue via a Dlat‐AMPK signaling axis to curb obesity. Cell Metabolism, 33(3), 565–580.e567.
    1. Chen, S., Wang, X., Jin, Y., Chen, X., Song, Q., Wei, G., & Li, L. (2024). Assessment of changes in body composition after 3 months of dulaglutide treatment. Diabetes, Metabolic Syndrome and Obesity, 17, 1301–1308.

MeSH terms

Substances

LinkOut - more resources